Monthly ReportJul 1–31, 2025
Anesthesiology, July 2025 edition
We read 96 papers and selected 5.
Summary
July 2025 anesthesiology research increasingly favored pragmatic, protocol-ready interventions supported by randomized trials and large evidence syntheses. Major themes included perioperative organ protection through dexmedetomidine, autonomic modulation, regional anesthesia, and tighter hemodynamic and oxygen management. Precision monitoring also advanced through esophageal pressure and recruitability metrics, rapid molecular or imaging diagnostics, and predictive analytics. The month additionally generated important de-implementation evidence, particularly against routine perioperative gabapentin, while translational studies identified neuroimmune, vascular, and peripheral nerve-barrier pathways for future therapy.
Selected Articles
1. Activation of Spinal Astrocyte α2A Adrenoceptors Protects Against Sepsis-Induced Heart Injury Through Inhibition of GABAergic Neuronal Necroptosis.
In a cecal-ligation-and-puncture sepsis model, spinal GABAergic neuronal necroptosis contributed to cardiac dysfunction. Dexmedetomidine activated spinal α2A-adrenoceptors, suppressed astrocyte inflammatory signaling involving C3, IL-6, and TNF-α, reduced neuronal injury, and preserved cardiac function. The findings define a spinal neuroimmune pathway linking sepsis to cardiomyopathy.
Impact: The study connects a commonly used anesthetic sedative with a previously underappreciated spinal neuroimmune mechanism of sepsis-associated cardiac injury, creating a strong translational rationale for clinical testing.
Clinical Implications: The results justify carefully designed clinical studies of dexmedetomidine for sepsis-associated cardiomyopathy, including evaluation of timing, dose, route, hemodynamic safety, and biomarkers for treatment selection.
Key Findings
- Sepsis induced spinal GABAergic neuronal necroptosis with RIPK1, RIPK3, and MLKL activation and reduced cardiac function.
- Necroptosis inhibition preserved spinal neurons and improved sepsis-associated cardiac dysfunction.
- Dexmedetomidine-mediated α2A-adrenoceptor activation reduced astrocyte C3, IL-6, and TNF-α signaling and prevented cardiomyopathy.
2. Neuronal toxicity and recovery from early bortezomib-induced neuropathy: blood-nerve barrier dysfunction without dorsal root ganglion damage.
Translational rat and patient data indicate that early bortezomib neuropathy is driven primarily by perineurial and blood-nerve barrier leakiness rather than major dorsal root ganglion injury. Recovery was associated with barrier resealing, normalization of axonal and cutaneous innervation changes, and increased cortactin and netrin-1 expression. The study identifies barrier repair as a potentially actionable therapeutic axis for chemotherapy-induced neuropathy.
Impact: It reframes early chemotherapy neuropathy as a potentially reversible barrier disorder rather than irreversible neuronal destruction and provides specific molecular hypotheses for neuroprotection and recovery.
Clinical Implications: Clinical development should evaluate small-fiber and skin-innervation measures as markers of disease progression and investigate netrin-1, cortactin, extracellular-matrix, or other barrier-repair strategies in preclinical and early-phase trials.
Key Findings
- Early bortezomib exposure caused perineurial leakiness, tactile allodynia, and cold allodynia with relatively modest dorsal root ganglion changes.
- Recovery correlated with resealing of the blood-nerve barrier and normalization of axonal and cutaneous innervation abnormalities.
- Netrin-1 and cortactin increased during recovery, whereas persistent pain was associated with reduced skin innervation and absent netrin-1 elevation.
3. Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial.
The multicenter phase 3 IsoCOMFORT trial randomized 96 mechanically ventilated children and found inhaled isoflurane non-inferior to intravenous midazolam for the proportion of time within the target COMFORT-B sedation range. Safety was comparable, and no treatment-related deaths occurred. The findings establish inhaled sedation as a viable option for selected pediatric intensive care settings.
Impact: As a multicenter phase 3 trial, it provides unusually strong evidence for expanding pediatric ICU sedation beyond intravenous agents and may influence equipment planning, staffing, and pharmacologic protocols.
Clinical Implications: PICUs with appropriate vaporizer, scavenging, monitoring, and staff expertise may consider isoflurane as an alternative for mechanically ventilated children, while continuing to evaluate longer-term neurodevelopmental and ICU outcomes.
Key Findings
- Time within the target COMFORT-B range was 68.94% with isoflurane versus 62.37% with midazolam, meeting the prespecified noninferiority margin.
- Serious adverse events were similar, and no treatment-related deaths occurred.
- The trial randomized children across 19 PICUs with standardized titration for approximately 48 hours.
4. Continuous versus bolus norepinephrine administration and arterial blood pressure stability during induction of general anaesthesia in high-risk noncardiac surgery patients: a randomised trial.
In a randomized trial of 72 high-risk noncardiac surgery patients, continuous norepinephrine infusion during induction reduced mean arterial pressure variability during the first 15 minutes compared with repeated manual boluses. The approach was feasible with arterial monitoring and pump availability, although effects on postoperative organ outcomes were not assessed.
Impact: It provides a simple, protocol-compatible hemodynamic intervention that directly addresses induction-related blood pressure variability, a potentially modifiable contributor to perioperative organ injury.
Clinical Implications: Continuous norepinephrine may be incorporated into induction bundles for selected high-risk patients with invasive arterial monitoring, but broader multicenter studies should evaluate organ outcomes, dosing algorithms, and safety.
Key Findings
- Continuous norepinephrine reduced generalized average real variability of mean arterial pressure during the first 15 minutes after induction.
- Arterial catheter monitoring enabled precise assessment of blood pressure stability.
- The randomized design demonstrated feasibility and short-term hemodynamic benefit, but postoperative organ outcomes were not reported.
5. Erector spinae plane block versus paravertebral block for major oncological breast surgery: a multicentre randomised controlled trial.
In a multicenter double-blind randomized trial of 292 patients undergoing major breast cancer surgery, erector spinae plane block did not meet noninferiority criteria compared with thoracic paravertebral block for early morphine rescue. ESPB produced higher mobilization pain scores and less reliable dermatomal coverage, although total morphine consumption and patient satisfaction were similar.
Impact: This large, practice-oriented randomized trial directly challenges the assumption that ESPB can routinely replace paravertebral block for major breast surgery and informs regional anesthesia training and resource allocation.
Clinical Implications: When expertise and contraindications permit, thoracic paravertebral block should remain the preferred technique for major oncological breast surgery. ESPB may be reserved for situations in which paravertebral block is unsuitable, with counseling regarding potentially higher early pain and incomplete coverage.
Key Findings
- ESPB failed noninferiority for morphine rescue within 2 hours: 75.2% versus 50.3% with paravertebral block.
- ESPB was associated with higher pain during mobilization and more frequent incomplete dermatomal coverage.
- No major complications occurred, and overall morphine consumption and patient satisfaction were similar.